274. Osteogenesis Imperfecta Clinical trials / Disease details
Clinical trials : 87 / Drugs : 103 - (DrugBank : 20) / Drug target genes : 14 - Drug target pathways : 76
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03735537 (ClinicalTrials.gov) | November 1, 2016 | 9/8/2018 | Treatment of Osteogenesis Imperfecta With Parathyroid Hormone and Zoledronic Acid | Treatment of Osteogenesis Imperfecta With Parathyroid Hormone and Zoledronic Acid | Osteogenesis Imperfecta | Drug: Teriparatide Pen Injector;Drug: Zoledronic Acid | University of Edinburgh | NHS Lothian | Recruiting | 18 Years | N/A | All | 380 | Phase 4 | Ireland;United Kingdom |